-
Eisai Co. Ltd. et al. v. Lupin Ltd. et al. DC
- 1:13-cv-01279
- D. Del.
- Judge: Leonard P. Stark
- Filed: 07/24/2013
- Closed: 10/13/2016
- Latest Docket Entry: 10/13/2016
- PACER
- Docket updated daily
3
Plaintiffs
9
Defendants
1
Accused
Product
3
Patents-in-Suit
1,178
Days in
Litigation
-
Eisai Co. Ltd. et al. v. Lupin Ltd. et al. DC
- 1:13-cv-01279
- D. Del.
- Judge: Leonard P. Stark
- Filed: 07/24/2013
- Closed: 10/13/2016
- Latest Docket Entry: 10/13/2016
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
-
Infringement
Glenmark Generics Incorporated USA
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic, ANDA No. 205075. | US 6,740,669 B1 | All Asserted Claims |
Infringement
Entry 222
|
| Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide, ANDA No. 205075. | US 7,750,028 B2 | All Asserted Claims |
Infringement
Entry 222
|
| Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof, ANDA No. 205075. | US 8,076,362 B2 | All Asserted Claims |
Infringement
Entry 222
|
Glenmark Generics Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic, ANDA No. 205075. | US 6,740,669 B1 | All Asserted Claims |
Infringement
Entry 222
|
| Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide, ANDA No. 205075. | US 7,750,028 B2 | All Asserted Claims |
Infringement
Entry 222
|
| Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof, ANDA No. 205075. | US 8,076,362 B2 | All Asserted Claims |
Infringement
Entry 222
|
Glenmark Pharmaceuticals Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic, ANDA No. 205075. | US 6,740,669 B1 | All Asserted Claims |
Infringement
Entry 222
|
| Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide, ANDA No. 205075. | US 7,750,028 B2 | All Asserted Claims |
Infringement
Entry 222
|
| Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof, ANDA No. 205075. | US 8,076,362 B2 | All Asserted Claims |
Infringement
Entry 222
|
Lupin Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 200mg rufinamide400mg rufinamide | US 6,740,669 B1 | All Asserted Claims |
Infringement
Entry 283
|
| 200mg rufinamide400mg rufinamide | US 7,750,028 B2 | All Asserted Claims |
Infringement
Entry 283
|
| 200mg rufinamide400mg rufinamide | US 8,076,362 B2 | All Asserted Claims |
Infringement
Entry 283
|
Lupin Pharmaceuticals Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 200mg rufinamide400mg rufinamide | US 6,740,669 B1 | All Asserted Claims |
Infringement
Entry 283
|
| 200mg rufinamide400mg rufinamide | US 7,750,028 B2 | All Asserted Claims |
Infringement
Entry 283
|
| 200mg rufinamide400mg rufinamide | US 8,076,362 B2 | All Asserted Claims |
Infringement
Entry 283
|
Roxane Laboratories Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 200mg, 400mg rufinamide | US 6,740,669 B1 | All Asserted Claims |
Infringement
Entry 284
|
| 200mg, 400mg rufinamide | US 7,750,028 B2 | All Asserted Claims |
Infringement
Entry 284
|
| 200mg, 400mg rufinamide | US 8,076,362 B2 | All Asserted Claims |
Infringement
Entry 284
|
